Changes in [(3)H]glibenclamide binding to mouse forebrain membranes during morphine tolerance

European Journal of Pharmacology
L G GonzálezJosé M Baeyens

Abstract

The characteristics of specific binding of the ATP-sensitive K(+) (K(ATP)) channel blocker [3H]glibenclamide to forebrain membranes (P(2) fraction, 4 degrees C) obtained from morphine-naive and -tolerant mice were evaluated. Morphine tolerance was induced by osmotic minipumps that released 45 mg/kg/day of morphine subcutaneously for 6 days. This treatment enhanced the antinociceptive ED(50) of morphine without changing its E(max). In morphine-naive animals, (1) both the association and the dissociation of [3H]glibenclamide were biphasic; (2) [3H]glibenclamide was displaced by other sulfonylureas (order of potency: glibenclamide>glipizide&z.Gt;tolbutamide) with pseudo-Hill coefficients lower than unity and biphasic Hofstee plots; and (3) Scatchard plots of saturation experiments were curvilinear, showed a Hill coefficient of 0.81+/-0.04 and suggested the presence of two binding sites with a K(D) of 0.13 and 3.17 nM and a B(max) of 12.30 and 84.47 fmol/mg protein, respectively. By contrast, in membranes obtained from morphine-tolerant animals, (1) the Scatchard plots showed only one population of binding sites with a K(D) of 0.87 nM and a B(max) of 77.99 fmol/mg protein, and the Hill coefficient was very close to unity (0.96+/-0....Continue Reading

References

Nov 3, 1992·Biochemical Pharmacology·M Gopalakrishnan, D J Triggle
Feb 22, 1991·Brain Research·S ZiniY Ben-Ari
May 25, 1991·European Journal of Pharmacology·J F FrenchJ G Sarmiento
Sep 21, 1990·European Journal of Pharmacology·M OcañaJ M Baeyens
Apr 28, 1989·Biochemical and Biophysical Research Communications·A SkattebølD J Triggle
Nov 1, 1985·Journal of Pharmacological Methods·G A McPherson
Jan 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S J Sherman, W A Catterall
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·S A Mackler, J H Eberwine
Apr 24, 1995·Brain Research·R B Raffa, R P Martinez
Jan 13, 1995·The Journal of Biological Chemistry·A KovoorC Chavkin
Aug 3, 1993·European Journal of Pharmacology·M OcañaJ M Baeyens
Oct 1, 1993·Neuropharmacology·I Niki, S J Ashcroft
Jan 12, 1993·European Journal of Pharmacology·M OcañaJ M Baeyens
Jan 11, 1996·European Journal of Pharmacology·L I RoblesJ M Baeyens
Mar 1, 1996·The Journal of Pharmacy and Pharmacology·B M Patil, P R Thakker
Sep 1, 1995·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·C LuS W Halvorsen
Oct 6, 1997·Science·E J Nestler, G K Aghajanian
Feb 11, 1998·Physiological Reviews·L Aguilar-BryanJ Bryan
Sep 23, 1998·Brain Research Bulletin·B E Levin, A A Dunn-Meynell
May 29, 1999·Molecular Pharmacology·H DörschnerM Schwanstecher
Jun 26, 1999·Circulation Research·B T Liang, G J Gross
Nov 24, 1999·Biological Psychiatry·E J NestlerG K Aghajanian
Dec 23, 1999·European Journal of Pharmacology·C UlensJ Tytgat

❮ Previous
Next ❯

Citations

Apr 21, 2004·Behavioural Pharmacology·M R ZarrindastB Djahanguiri
Jun 28, 2003·Natural Product Reports·Kenneth W Bentley
May 21, 2003·The Journal of Pharmacology and Experimental Therapeutics·Willias MasochaJosé M Baeyens
Mar 7, 2008·The International Journal of Neuroscience·Omid KhalilzadehMohammad R Zarrindast
Jan 9, 2013·Molecular Pharmacology·Lin GuoXuechu Zhen
Dec 31, 2002·European Journal of Pharmacology·Gyöngyi HorvathJose Manuel Baeyens
Jul 22, 2009·Neuroscience Research·Haiping DengWolfgang Schwarz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.